眼薬の世界市場予測2016-2026

◆英語タイトル:Ophthalmic Drugs Market Forecast 2016-2026
◆商品コード:VGAIN81924
◆発行会社(調査会社):visiongain
◆発行日:2016年7月
◆ページ数:334
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥291,854見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥437,854見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥729,854見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、眼薬の世界市場について調査・分析し、眼薬の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 眼薬の概要

3. 眼薬の世界市場

4. 網膜障害治療薬市場:市場分析・予測

5. アレルギー、炎症、感染症治療薬市場:市場分析・予測

6. 緑内障治療薬市場:市場分析・予測

7. ドライアイ治療薬市場:市場分析・予測

8. 眼薬の主要国市場

9. 眼薬市場における主要企業

10. 眼薬:研究開発パイプライン

11. 眼薬市場の定性分析

12. 結論

13. 用語集
【レポートの概要】

What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.

Our 334-page report provides 238 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju

The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

Leading companies and potential for market growth
Retinal disorder drugs will remain the leading ophthalmic submarket to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of leading companies, including these:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Ophthalmic Drugs Market Forecast 2016-2026 report helps you
In summary, our 334-page report gives you the following knowledge:
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
• Revenue forecasts to 2026 for 25 leading drugs – discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Avastin, Visudyne, Jetrea, Pataday, Vigamox, Patanol, TobraDex, Cravit, AzaSite, Acular, Lumigan and Ganfort, Xalatan/Xalacom, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Azopt, Trusopt, Zioptan, Cosopt, Tapros/Taflotan, Restasis, Refresh, Hyalein and Diquas
• Revenue forecasts to 2026 for the 9 leading companies in the market – discover the industry’s prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer and Senju
• Assessment of 50 pipeline products – analysis of clinical trial progress and drug candidate potential across all ophthalmic indications
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report

3. The Global Ophthalmic Drugs Market, 2016-2026
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2015
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2016-2026
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2016-2026

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Leading Products in the Retinal Disorder Drugs Market, 2015
4.2 Retinal Disorders: Market Trends And Developments, 2016
4.2.1 The Rise And Rise Of Eylea
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2016-2026
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2016-2026
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals For Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2016-2026
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2016-2026
4.6.2 Less Frequent Dosing Approved In US For Lucentis
4.6.3 New Indications For Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2016-2026
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2016-2026
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2016-2026
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2016-2026

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2016-2026
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2015
5.2 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2016
5.2.1 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory And Infective Drugs: Market Forecast 2016-2026
5.3.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2016-2026
5.4 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2016-2026
5.5.2 Impending Generic Competition For Patanol And Pataday
5.5.3 Approval Of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2016-2026
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2016-2026
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development And Commercialisation Of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2016-2026
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2016-2026
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 5.9.1 Acular: Sales Forecast 2016-2026
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2016-2026
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2026

6. Glaucoma Drugs Market: Market Analysis And Forecast 2016-2026
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2015
6.2 Glaucoma Drugs: Market Trends And Developments, 2016
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2016-2026
6.4.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2016-2026
6.5 Leading Drugs For The Treatment Of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2016-2026
6.7 Xalatan And Xalacom (latanoprost) – Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2016-2026
6.8 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.8.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2016-2026
6.9 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.9.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2016-2026
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement With Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2016-2026
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2016-2026
6.11 Azopt (brinzolamide) – Novartis
6.11.1 Azopt: Sales Forecast 2016-2026
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2016-2026
6.13 Zioptan (tafluprost) – Akorn
6.13.1 Zioptan: Sales Forecast 2016-2026
6.14 Other Glaucoma Drugs: Sales Forecast 2016-2026

7. Dry Eye Drugs Market: Market Analysis And Forecast 2016-2026
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2015
7.2 Dry Eye Drugs: Market Trends And Developments, 2016
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2016-2026
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2016-2026
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2016-2026
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2016-2026
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2016-2026
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2016-2026
7.9 Other Dry Eye Drugs: Sales Forecast 2016-2026
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2016-2026

8. Leading National Markets For Ophthalmic Drugs, 2016-2026
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares By Region, 2016-2026
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2016-2026
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2016-2026
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2016-2026
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2016-2026
8.7 8.7 China
8.7.1 Expansion Of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2016-2026
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2016-2026

9. Leading Companies in the Ophthalmic Drugs Market, 2016-2026
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies In The Ophthalmic Drugs Market, 2015
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2016-2026
9.2.2 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2016-2026
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.3.2 Novartis: Sales Forecast 2016-2026
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
9.3.4 Novartis: Recent Developments
9.3.4.1 Novartis Restructures Following Strategic Review
9.3.4.2 Novartis Licenses Ophthotech’s Fovista
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.4.2 Regeneron: Recent Developments
9.4.2.1 Expanding Indications For Eylea
9.4.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.4.3 Regeneron: Sales Forecast 2016-2026
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.5.2.2 How Real Is The Threat Of Generic Restasis?
9.5.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.5.3 Allergan: Sales Forecast 2016-2026
9.5.4 Allergan: Ophthalmic Drugs Development Pipeline, 2016
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
9.6.1.1 Lucentis: US Sales Forecast 2016-2026
9.6.2 Roche: Sales Forecast 2016-2026
9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2016-2026
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
9.7.5 Valeant: Difficult End to 2015 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.8.2 Santen: Recent Developments
9.8.2.1 Santen Acquires Novagali Pharma
9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.8.3 Santen: Sales Forecast 2016-2026
9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2016-2026
9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2016
9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.10.1.2 Macugen – Valeant/Pfizer
9.10.2 Pfizer: Recent Developments
9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
9.10.2.2 Pfizer Attempts Merger with Allergan
9.10.3 Pfizer: Sales Forecast 2016-2026
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2016
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2016-2026
9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016
9.11.3.1 Y 39983 (SNJ 1656)
9.11.3.2 Difluprednate (SJE-2079)

10. Ophthalmic Drugs: Research And Development Pipeline, 2016-2026
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2016
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) – Abbott
10.3.3 Iluvien (fluocinolone) – Alimera Sciences
10.4 Drugs In Phase 3 Development For Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-Factor D Fab) – Roche
10.4.4 MC-1101 (hydralazine) – MacuCLEAR
10.4.5 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) – R-Tech Ueno
10.5 Drugs In Phase 2 Development For Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.5.3 AGN208397 (beclomethasone) – Allergan
10.5.4 CPC 551 – Colby Pharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) – Novartis
10.5.8 Intravitreal brimonidine implant – Allergan
10.5.9 Optina (danazol) – Ampio Pharmaceuticals
10.5.10 PF-655 (synthetic siRNA) – Quark/Pfizer
10.5.11 Premiplex (SHP-607) – Shire
10.5.12 Renexus (ciliary neurotrophic factor) – Neurotech
10.5.13 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.6 Drugs In Phase 1 and Pre-clinical Development for Retinal Disorders
10.6.1 BDM-E – BioDiem
10.6.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.6.3 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.6.4 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2016
10.8 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.8.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.8.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.8.3 KPI-121 (loteprednol etabonate) – Kala
10.9 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.9.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.9.2 FST-100 (povidone-iodine/dexamethasone) – Shire
10.9.3 NVC-422 (auriclosene) – NovaBay
10.9.4 Sarilumab – Regeneron
10.10 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.10.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.11 Drugs For Glaucoma: Development Pipeline, 2016
10.12 Drugs In Phase 2&3 Development For Glaucoma
10.12.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.12.2 AMA0076 (ROCK inhibitor) – Amakem
10.12.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.13 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.14 Drugs For Dry Eye: Development Pipeline, 2016
10.15 Drugs In Phase 3 Development For Dry Eye
10.15.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.15.2 Lifitegrast (integrin antagonist) – Shire
10.15.3 Tavilermide (formerly MIM-D3 tyrosine kinase receptor antagonist) – Allergan
10.15.4 SI-614 (modified hyaluronate) – Seikagaku
10.16 Drugs In Phase 2 Development For Dry Eye
10.16.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.16.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.17 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.17.1 Brimonidine For Eye Whitening – Valeant
10.17.2 GS-101 (aganirsen) – Gene Signal
10.17.3 Omidria (phenylephrine/ketorolac) – Omeros

11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2016-2026
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances In Drug Delivery Technologies
11.3.3 Support For Reimbursement And Payment Approvals
11.3.4 Gene Therapy And RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications For Drugs
11.3.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence To Treatment
11.4.2 High Treatment Burden On Patients And Healthcare Providers
11.4.3 Under-Diagnosis And Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact Of A Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma And Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need In Many Disease Areas
11.5.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation In The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers

12. Conclusions
12.1 Overview Of Current Market Conditions And Market Forecast, 2015-2026
12.2 Leading Sectors In Ophthalmic Drugs In 2015
12.3 Leading Regions In The Ophthalmic Drugs Market In 2015
12.4 Leading Companies In The Ophthalmic Drugs Market, 2015
12.5 What Does The Future Hold For Ophthalmic Drugs?

13. Glossary

List of Tables
Table 1.1 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2015-2026 (Redacted Data)
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments For Glaucoma, 2016
Table 2.3 Drug Treatments For Age-Related Macular Degeneration, 2016
Table 2.4 Drug Treatments For Ocular Allergy, 2016
Table 2.5 Drug Treatments For Ocular Inflammatory Disease, 2016
Table 2.6 Drug Treatments For Eye Infections, 2016
Table 2.7 Clinical Trial Phases, 2016
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2015
Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2015-2026
Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2020, 2020-2026, 2015-2026
Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2015, 2020, 2026
Table 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2015
Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR(%) and CAGR(%), 2015-2026
Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2015
Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2015
Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2015
Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2015-2026
Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2015
Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2015-2026
Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2020, 2020-2026, and 2015-2026
Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2015, 2020, and 2026
Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.7 The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2015-2026
Table 8.8 The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2015
Table 8.9 The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.10 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2015, 2020, 2026
Table 8.11 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.12 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.13 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.14 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.15 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.16 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.17 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.19 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.21 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.22 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.23 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.24 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.25 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.26 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.27 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.28 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.29 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.30 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 8.31 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.32 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2015
Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2015-2026
Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2015, 2020, 2026
Table 9.4 Novartis: Company Overview, 2016
Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.6 Regeneron: Company Overview, 2016
Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.8 Allergan: Company Overview, 2016
Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.10 Roche: Company Overview, 2015
Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.13 Valeant: Company Overview, 2016
Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.15 Santen: Company Overview, 2015
Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.17 Bayer: Company Overview, 2015
Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.19 Pfizer: Company Overview, 2016
Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 9.21 Senju: Company Overview, 2016
Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2016 (continued)
Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs, 2016
Table 10.8 Glaucoma Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.9 Dry Eye Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.10 Dry Eye Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.11 Other Pipeline Products for Ophthalmic Conditions, 2016
Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2016-2026
Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2015-2026
Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases from 2015
Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2015, 2020, 2026
Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2015, 2020, 2026

List of Figures
Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2016
Figure 2.1 Structure Of The Human Eye
Figure 2.2 Estimated Global Prevalence Of Visual Impairment (millions of people), 2014
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification Of Glaucoma, 2016
Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2015
Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2020
Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2020-2026
Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2026
Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2015
Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2020
Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2026
Figure 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m), 2015
Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2015-2026
Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2015
Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2020
Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2026
Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2015-2026
Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2015-2026
Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2015-2026
Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2015-2026
Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2015-2026
Figure 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2015
Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2015-2026
Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2015
Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2020
Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2026
Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2015-2026
Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2015-2026
Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2015-2026
Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2015-2026
Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2015-2026
Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2015-2026
Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2015-2026
Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2015-2026
Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2015
Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2015-2026
Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2015
Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2020
Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2026
Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2015-2026
Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2015-2026
Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2015-2026
Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2015-2026
Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2015-2026
Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2015-2026
Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2015-2026
Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2015
Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2015
Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2020
Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2026
Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2015-2026
Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2015-2026
Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2015-2026
Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2015-2026
Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2015
Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2020
Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2020-2026
Figure 8.6 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2026
Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2015
Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2020
Figure 8.9 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2026
Figure 8.10 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.11 The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2015
Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
Figure 8.13 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2015
Figure 8.14 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2020
Figure 8.15 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2026
Figure 8.16 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.18 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.19 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.21 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.22 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.23 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.24 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.25 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 8.26 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2015
Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%) by Leading Companies, 2015-2026
Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2015
Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2020
Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2026
Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2015-2026
Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2016
Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2015, 2020, 2026
Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2015-2026

★調査レポート[眼薬の世界市場予測2016-2026]販売に関する免責事項
★調査レポート[眼薬の世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆